When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...

These drugs belong to a class known as glucagon-like peptide receptor agonists (GLP-1RAs), which mimic a natural hormone that ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Ozempic may help reduce alcohol cravings, according to a new study. But you shouldn't use them to help curb drinking habits ...

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

The two organizations will produce educational materials about the medicine and its importance for people living ... together on a campaign to raise awareness about the importance of glucagon.

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Research shows bimagrumab may prevent muscle and bone loss associated with weight loss medications like Wegovy, offering hope ...